Chu-Toulouse

Toulouse 31300

4 studies enrolling now · 14 studies all time

What they study most

Advanced Colorectal Cancer, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Colitis, Ulcerative, Depressive Disorder, Major, Diabetic Macular Edema, Extreme Prematurity - Less Than 28 Weeks, Frontotemporal Dementia, Hemi-retinal Vein Occlusion, Hepatitis Delta Virus, Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis, KIT D816V Mutation

Studies at this site

• Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis — Recruiting now
• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis — Recruiting now
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products — Running, not enrolling
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) — Running, not enrolling
• Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer — Completed
• 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide — Completed
• Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma — Stopped early
• Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV — Status unconfirmed
• (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation — Completed
• Masitinib for the Treatment of Severe Mast Cell Activation Syndrome — Status unconfirmed
• Study of Room Air Versus 60% Oxygen for Resuscitation of Premature Infants — Stopped early